Skip to main content

Table 7 Change in HbA1c with DPP-4i use, N = 105

From: Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital

 Pre DPP-4i usePost DPP-4i useMean difference ± 95% CIP value£P value¥
Age (years old)
 < 608.7 ± 2.07.8 ± 1.70.89 (0.44,1.34)< 0.0001*0.963
 ≥ 608.3 ± 1.57.4 ± 1.60.91 (0.45,1.36)< 0.0001*
Type of DPP-4i
 Vildagliptin8.1 ± 1.57.4 ± 1.60.68 (0.21, 1.14)0.006*0.011¢
 Sitagliptin9.2 ± 2.27.5 ± 1.81.66 (0.95, 2.37)< 0.0001*
 Saxagliptin8.4 ± 1.48.0 ± 1.50.33 (−0.03, 0.67)0.052
 Linagliptin8.8 ± 2.18.1 ± 2.10.76(−1.12, 2.64)0.370
Gender
 Male8.5 ± 1.87.4 ± 1.51.13 (0.59, 1.66)< 0.0001*0.162
 Female8.6 ± 1.87.9 ± 1.80.68 (0.31, 1.04)< 0.0001*
Therapy
 FDC8.6 ± 1.87.6 ± 1.70.99 (0.60, 1.38)< 0.0001*0.455
 Single pill8.5 ± 1.87.8 ± 1.70.74 (0.18, 1.30)0.011*
Insulin
 Yes9.0 ± 2.08.2 ± 1.90.81 (0.37, 1.25)< 0.0001*0.554
 No8.0 ± 1.57.0 ± 1.11.00 (0.53, 1.48)< 0.0001*
Sulphonylurea
 Yes8.2 ± 1.17.2 ± 1.10.96 (0.36, 1.56)0.003*0.824
 No8.7 ± 2.07.8 ± 1.80.88 (0.49, 1.26)< 0.0001*
  1. £Paired T-test conducted to compare pre and post DPP-4i HbA1c
  2. ¥Independent T-test and ANOVA conducted to compare the HbA1c difference between the groups
  3. ¢Post-hoc analysis (LSD) conducted for types of DPP-4i
  4. Values reported as mean ± SD
  5. *p value is significant at< 0.05